{"organizations": [], "uuid": "d28f05ddca454431f3271a06057ee28823e657a2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-galapagos-announces-isabela-phase/brief-galapagos-announces-isabela-phase-3-program-in-ipf-idUSFWN1RP0X1", "country": "US", "domain_rank": 408, "title": "BRIEF-Galapagos Announces Isabela Phase 3 Program In IPF", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-12T23:05:00.000+03:00", "replies_count": 0, "uuid": "d28f05ddca454431f3271a06057ee28823e657a2"}, "author": "", "url": "https://www.reuters.com/article/brief-galapagos-announces-isabela-phase/brief-galapagos-announces-isabela-phase-3-program-in-ipf-idUSFWN1RP0X1", "ord_in_thread": 0, "title": "BRIEF-Galapagos Announces Isabela Phase 3 Program In IPF", "locations": [], "entities": {"persons": [], "locations": [{"name": "isabela", "sentiment": "none"}], "organizations": [{"name": "brief-galapagos announces isabela phase", "sentiment": "negative"}, {"name": "isabela", "sentiment": "none"}, {"name": "galapagos nv", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 12, 2018 / 8:06 PM / Updated 4 minutes ago BRIEF-Galapagos Announces Isabela Phase 3 Program In IPF Reuters Staff \nApril 12 (Reuters) - Galapagos NV: * GALAPAGOS ANNOUNCES ISABELA PHASE 3 PROGRAM IN IPF \n* ANNOUNCES DESIGN OF A WORLDWIDE PHASE 3 PROGRAM TO EVALUATE GLPG1690 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS \n* GLOBAL PHASE 3 PROGRAM IS EXPECTED TO CONSIST OF TWO IDENTICALLY DESIGNED TRIALS, ISABELA 1 AND ISABELA 2 \n* PHASE 3 PROGRAM IS EXPECTED TO START DOSING IN SECOND HALF OF 2018 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-12T23:05:00.000+03:00", "crawled": "2018-04-12T23:12:57.014+03:00", "highlightTitle": ""}